文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Lipoprotein(a) and residual vascular risk in statin-treated patients with first acute ischemic stroke: A prospective cohort study.

作者信息

Wang Lanjing, Liu Lijun, Zhao Yanhong, Chu Min, Teng Jijun

机构信息

Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.

Department of Neurology, Minhang Hospital, Fudan University, Qingdao, China.

出版信息

Front Neurol. 2022 Nov 3;13:1004264. doi: 10.3389/fneur.2022.1004264. eCollection 2022.


DOI:10.3389/fneur.2022.1004264
PMID:36408516
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9671150/
Abstract

OBJECTIVES: Statins either barely affect or increase lipoprotein(a) [Lp(a)] levels. This study aimed to explore the factors correlated to the change of Lp(a) levels as well as the relationship between Lp(a) and the recurrent vascular events in statin-treated patients with first acute ischemic stroke (AIS). METHODS: Patients who were admitted to the hospital with first AIS from October 2018 to September 2020 were eligible for inclusion. Correlation between the change of Lp(a) levels and potential influencing factors was assessed by linear regression analysis. Cox proportional regression models were used to estimate the association between Lp(a) and recurrent vascular events including AIS, transient ischemic attack, myocardial infarction and coronary revascularization. RESULTS: In total, 303 patients, 69.6% males with mean age 64.26 ± 11.38 years, completed the follow-up. During the follow-up period, Lp(a) levels increased in 50.5% of statin-treated patients and the mean percent change of Lp(a) levels were 14.48% (95% CI 6.35-22.61%). Creatinine (β = 0.152, 95% CI 0.125-0.791, = 0.007) and aspartate aminotransferase (AST) (β = 0.160, 95% CI 0.175-0.949, = 0.005) were positively associated with the percent change of Lp(a) levels. During a median follow-up of 26 months, 66 (21.8%) patients had a recurrent vascular event. The median time period between AIS onset and vascular events recurrence was 9.5 months (IQR 2.0-16.3 months). The on-statin Lp(a) level ≥70 mg/dL (HR 2.539, 95% CI 1.076-5.990, = 0.033) and the change of Lp(a) levels (HR 1.003, 95% CI 1.000-1.005, = 0.033) were associated with the recurrent vascular events in statin-treated patients with first AIS. Furthermore, the on-statin Lp(a) levels ≥70 mg/dL (HR 3.612, 95% CI 1.018-12.815, = 0.047) increased the risk of recurrent vascular events in patients with low-density lipoprotein cholesterol (LDL-C) levels < 1.8 mmol/L. CONCLUSIONS: Lp(a) levels increased in half of statin-treated patients with first AIS. Creatinine and AST were positively associated with the percent change of Lp(a) levels. Lp(a) is a determinant of residual vascular risk and the change of Lp(a) is positively associated with the risk of recurrent vascular events in these patients.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2a8/9671150/f5220dee2dc0/fneur-13-1004264-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2a8/9671150/15e472451127/fneur-13-1004264-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2a8/9671150/d14acba6cb67/fneur-13-1004264-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2a8/9671150/0fbea0dad441/fneur-13-1004264-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2a8/9671150/f5220dee2dc0/fneur-13-1004264-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2a8/9671150/15e472451127/fneur-13-1004264-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2a8/9671150/d14acba6cb67/fneur-13-1004264-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2a8/9671150/0fbea0dad441/fneur-13-1004264-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2a8/9671150/f5220dee2dc0/fneur-13-1004264-g0004.jpg

相似文献

[1]
Lipoprotein(a) and residual vascular risk in statin-treated patients with first acute ischemic stroke: A prospective cohort study.

Front Neurol. 2022-11-3

[2]
Lipoprotein(a) Levels and Recurrent Vascular Events After First Ischemic Stroke.

Stroke. 2017-1

[3]
Effect of Lipoprotein(a) on Stroke Recurrence Attenuates at Low LDL-C (Low-Density Lipoprotein) and Inflammation Levels.

Stroke. 2022-8

[4]
Statins Therapy Improves Acute Ischemic Stroke in Patients with Cardio-metabolic Disorders Measured by Lipoprotein-Associated Phospholipase A2 (Lp-PLA2): New Focal Point.

Neurol India. 2021

[5]
Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN.

Atherosclerosis. 2017-6-15

[6]
The correlation between lipoprotein(a) elevations and the risk of recurrent cardiovascular events in CAD patients with different LDL-C levels.

BMC Cardiovasc Disord. 2022-4-15

[7]
Oxidized low-density lipoprotein (LDL) and LDL cholesterol are associated with outcomes of minor stroke and TIA.

Atherosclerosis. 2020-3

[8]
Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication.

J Am Coll Cardiol. 2013-8-21

[9]
Lipoprotein(a): A Residual Cardiovascular Risk Factor in Statin-Treated Stroke Survivors: Insights From the SPARCL Trial.

JACC Adv. 2023-8-22

[10]
Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.

JAMA Cardiol. 2018-9-1

引用本文的文献

[1]
The Association of Lipoprotein(a) and Stroke Recurrence: A Systematic Review and Meta-Analysis.

J Stroke. 2025-5

[2]
Lipoprotein(a) and panvascular disease.

Lipids Health Dis. 2025-5-24

[3]
Lipoprotein(a) as a Stroke Biomarker: Pathophysiological Pathways and Therapeutic Implications.

J Clin Med. 2025-4-25

[4]
Lipoprotein (a) and cerebrovascular disease.

J Int Med Res. 2024-7

[5]
Intermediate and long-term residual cardiovascular risk in patients with established cardiovascular disease treated with statins.

Front Cardiovasc Med. 2024-1-15

本文引用的文献

[1]
Lp(a): a New Pathway to Target?

Curr Atheroscler Rep. 2022-11

[2]
The Potential Clinical Benefit of Lowering Lipoprotein(a).

JAMA. 2022-5-3

[3]
Independent Association of Lipoprotein(a) and Coronary Artery Calcification With Atherosclerotic Cardiovascular Risk.

J Am Coll Cardiol. 2022-3-1

[4]
Repeat Measures of Lipoprotein(a) Molar Concentration and Cardiovascular Risk.

J Am Coll Cardiol. 2022-2-22

[5]
The year in cardiovascular medicine 2021: dyslipidaemia.

Eur Heart J. 2022-2-22

[6]
Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis.

Eur J Prev Cardiol. 2022-5-5

[7]
Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Société Francophone d'Athérosclérose (NSFA).

Arch Cardiovasc Dis. 2021-12

[8]
Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.

Hepatol Commun. 2022-3

[9]
Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation.

Pharmacol Res. 2021-7

[10]
Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics.

Cardiovasc Res. 2022-3-25

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索